Omicron news
Covid’s Omicron Variant Can Increase Risk for Diabetes …
for 22 timer siden — People infected with Covid-19 during the omicron era face an increased risk of diabetes and related diseases, according to a study showing …
Omicron News, Research
Worldwide, BA.1 account for most of Omicron-cases. However, in Denmark BA.2 is gaining ground. Updated 20 January 2022. The subvariant BA.2 accounted for …
Now, an Omicron variant, BA.2, accounts for almost half of all …
Now, an Omicron variant, BA.2, accounts for almost half of all Danish Omicron-cases
3. feb. 2023 — In early 2023, a new Omicron subvariant called XBB.1.5, the most transmissible strain of the virus so far, was predominant in the U.S. Cases …
So far, three subvariants of Omicron have been described: BA.1, BA.2 and BA.3. Worldwide, BA.1 account for most of Omicron-cases. However, in Denmark BA.2 is gaining ground.
Omicron and its Subvariants: A Guide to What We Know
Omicron and its Subvariants: A Guide to What We Know > News > Yale Medicine
for 22 timer siden — Several studies have suggested that Omicron causes less severe Covid-19 infections than the variants that preceded it. “One might expect that …
Experts are following the data around COVID-19 Omicron variant—and various subvariants that have emerged—in an effort to learn more about the highly transmissible virus strain.
Risk of developing diabetes after Covid-19 continued in … – CNN
27. okt. 2022 — Overall summaryThe Omicron variant of concern remains the … initial waves of Omicron infection, and further evolution of Omicron variants, …
One year since the emergence of COVID-19 virus variant …
One year since the emergence of COVID-19 virus variant Omicron
21. dec. 2022 — What are omicron symptoms: Omicron subvariants may have different symptoms than previous Covid strains. What to look out for.
What has changed, and why there hasn’t been a new variant of concern
TAG-VE statement on Omicron sublineages BQ.1 and XBB
As part of its ongoing work to track variants, WHO’s Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) met on the 24 October 2022 to discuss the latest evidence on the Omicron variant of concern, and how its evolution is currently unfolding, in light of high levels of population immunity in many settings and country differences in the immune landscape. In particular, the public health implications of the rise of some Omicron variants, specifically XBB and its sublineages (indicated as XBB*), as well as BQ.1 and its sublineages (indicated as BQ.1*), were discussed.Based on currently available evidence, the TAG-VE does not feel that the overall phenotype of XBB* and BQ.1* diverge sufficiently from each other, or from other Omicron lineages with additional immune escape mutations, in terms of the necessary public health response, to warrant the designation of new variants of concern and assignment of a new label.The two sublineages remain part of Omicron, which continues to be a variant of concern.This decision will be reassessed regularly. If there is any significant development that warrant a change in public health strategy, WHO will promptly alert Member States and the public.XBB*XBB* is a recombinant of BA.2.10.1 and BA.2.75 sublineages. As of epidemiological week 40 (3 to 9 October), from the sequences submitted to GISAID, XBB* has a global prevalence of 1.3% and it has been detected in 35 countries. The TAG-VE discussed the available data on the growth advantage of this sublineage, and some early evidence on clinical severity and reinfection risk from Singapore and India, as well as inputs from other countries. There has been a broad increase in prevalence of XBB* in regional genomic surveillance, but it has not yet been consistently associated with an increase in new infections. While further studies are needed, the current data do not suggest there are substantial differences in disease severity for XBB* infections. There is, however, early evidence pointing at a higher reinfection risk, as compared to other circulating Omicron sublineages. Cases of reinfection were primarily limited to those with initial infection in the pre-Omicron period. As of now, there are no data to support escape from recent immune responses induced by other Omicron lineages. Whether the increased immune escape of XBB* is sufficient to drive new infection waves appears to depend on the regional immune landscape as affected by the size and timing of previous Omicron waves, as well as the COVID-19 vaccination coverage. BQ.1*BQ.1* is a sublineage of BA.5, which carries spike mutations in some key antigenic sites, including K444T and N460K. In addition to these mutations, the sublineage BQ.1.1 carries an additional spike mutation in a key antigenic site (i.e. R346T). As of epidemiological week 40 (3 to 9 October), from the sequences submitted to GISAID, BQ.1* has a prevalence of 6% and it has been detected in 65 countries. While there are no data on severity or immune escape from studies in humans, BQ.1* is showing a significant growth advantage over other circulating Omicron sublineages in many settings, including Europe and the US, and therefore warrants close monitoring. It is likely that these additional mutations have conferred an immune escape advantage over other circulating Omicron sublineages, and therefore a higher reinfection risk is a possibility that needs further investigation. At this time there is no epidemiologic data to suggest an increase in disease severity. The impact of the observed immunological changes on vaccine escape remains to be established. Based on currently available knowledge, protection by vaccines (both the index and the recently introduced bivalent vaccines) against infection may be reduced but no major impact on protection against severe disease is foreseen. Overall summaryThe Omicron variant of concern remains the dominant variant circulating globally, accounting for nearly all sequences reported
Latest News & Videos, Photos about omicron
Omicron subvariant symptoms: How quickly do … – NBC News
Omicron subvariant symptoms: How quickly do omicron symptoms appear?
What are omicron symptoms: Omicron subvariants may have different symptoms than previous Covid strains. What to look out for.
Omicron XBB.1.5 does not have mutations known to make …
Covid news: Omicron XBB.1.5 doesn’t have mutations known to make people sicker
The WHO said omicron XBB.1.5 does not have any mutations known to make people sicker but added that it needs more data to draw conclusions about its severity.
Keywords: omicron news
